Compare Natera Inc. Common Stock (NTRA) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Short Term Corporate Bond ETF — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Natera Inc. Common Stock and Vanguard Short Term Corporate Bond ETF are close in size by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Short Term Corporate Bond ETF for 54 Days on average.
| NTRA | VCSH | |
|---|---|---|
Market Cap | $57.03B | $51.90B |
Volume | 1,131,157 | 12,465,005 |
Sector | Health | Fixed Income |
52-Week High | $425.64 | $80.20 |
52-Week Low | $179.42 | $77.03 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VCSH trades at $77.32, down slightly by 0.05% today, with a bearish technical signal from moving averages and oscillators. The ETF maintains a competitive 4.5% dividend yield with consistent quarterly distributions of $0.30. Recent news highlights VCSH's low 0.03% expense ratio and short 2.7-year duration, positioning it as a high-quality short-term corporate bond option amid rising rate concerns.
Outlook remains cautious due to tight credit spreads and limited price appreciation potential. The ETF offers income stability but faces headwinds from potential spread widening and competition from broader bond ETFs. Risk-reward appears balanced for income-focused investors seeking short-duration corporate exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
